129 related articles for article (PubMed ID: 22266834)
1. Prevention of postoperative recurrence of Crohn's disease by Adalimumab: a case series.
Savarino E; Dulbecco P; Bodini G; Assandri L; Savarino V
Eur J Gastroenterol Hepatol; 2012 Apr; 24(4):468-70. PubMed ID: 22266834
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of adalimumab for the management of inflammatory bowel disease in the clinical setting.
Trinder MW; Lawrance IC
J Gastroenterol Hepatol; 2009 Jul; 24(7):1252-7. PubMed ID: 19220669
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness and safety of local adalimumab injection in patients with fistulizing perianal Crohn's disease: a pilot study.
Tonelli F; Giudici F; Asteria CR
Dis Colon Rectum; 2012 Aug; 55(8):870-5. PubMed ID: 22810472
[TBL] [Abstract][Full Text] [Related]
4. Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial.
Savarino E; Bodini G; Dulbecco P; Assandri L; Bruzzone L; Mazza F; Frigo AC; Fazio V; Marabotto E; Savarino V
Am J Gastroenterol; 2013 Nov; 108(11):1731-42. PubMed ID: 24019080
[TBL] [Abstract][Full Text] [Related]
5. Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study.
Feagan BG; Panaccione R; Sandborn WJ; D'Haens GR; Schreiber S; Rutgeerts PJ; Loftus EV; Lomax KG; Yu AP; Wu EQ; Chao J; Mulani P
Gastroenterology; 2008 Nov; 135(5):1493-9. PubMed ID: 18848553
[TBL] [Abstract][Full Text] [Related]
6. Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn's disease: results from the CHARM trial.
Colombel JF; Sandborn WJ; Rutgeerts P; Kamm MA; Yu AP; Wu EQ; Pollack PF; Lomax KG; Chao J; Mulani PM
Am J Gastroenterol; 2009 May; 104(5):1170-9. PubMed ID: 19352339
[TBL] [Abstract][Full Text] [Related]
7. Adalimumab in prevention of postoperative recurrence of Crohn's disease in high-risk patients.
Aguas M; Bastida G; Cerrillo E; Beltrán B; Iborra M; Sánchez-Montes C; Muñoz F; Barrio J; Riestra S; Nos P
World J Gastroenterol; 2012 Aug; 18(32):4391-8. PubMed ID: 22969204
[TBL] [Abstract][Full Text] [Related]
8. [Level of adalimumab and its antibody titers define the effectiveness of the biological (anticytokine) therapy in Crohn's disease].
Lazebnik LB; Sagynbaeva VÉ
Eksp Klin Gastroenterol; 2013; (7):18-22. PubMed ID: 24772870
[TBL] [Abstract][Full Text] [Related]
9. Prevention of postoperative recurrence of Crohn's disease by infliximab.
Sorrentino D; Terrosu G; Avellini C; Beltrami CA; Bresadola V; Toso F
Eur J Gastroenterol Hepatol; 2006 Apr; 18(4):457-9. PubMed ID: 16538123
[TBL] [Abstract][Full Text] [Related]
10. Direct retrospective comparison of adalimumab and infliximab in preventing early postoperative endoscopic recurrence after ileocaecal resection for crohn's disease: results from the MULTIPER database.
Kotze PG; Yamamoto T; Danese S; Suzuki Y; Teixeira FV; de Albuquerque IC; Saad-Hossne R; de Barcelos IF; da Silva RN; da Silva Kotze LM; Olandoski M; Sacchi M; Yamada A; Takeuchi K; Spinelli A
J Crohns Colitis; 2015 Jul; 9(7):541-7. PubMed ID: 25820017
[TBL] [Abstract][Full Text] [Related]
11. Low serum trough levels are associated with post-surgical recurrence in Crohn's disease patients undergoing prophylaxis with adalimumab.
Bodini G; Savarino V; Peyrin-Biroulet L; de Cassan C; Dulbecco P; Baldissarro I; Fazio V; Giambruno E; Savarino E
Dig Liver Dis; 2014 Nov; 46(11):1043-6. PubMed ID: 25169962
[TBL] [Abstract][Full Text] [Related]
12. Infliximab prevents Crohn's disease recurrence after ileal resection.
Regueiro M; Schraut W; Baidoo L; Kip KE; Sepulveda AR; Pesci M; Harrison J; Plevy SE
Gastroenterology; 2009 Feb; 136(2):441-50.e1; quiz 716. PubMed ID: 19109962
[TBL] [Abstract][Full Text] [Related]
13. Distinctive histopathologic phenotype in resection specimens from patients with Crohn's disease receiving anti-TNF-α therapy.
Schaeffer DF; Walsh JC; Kirsch R; Waterman M; Silverberg MS; Riddell RH
Hum Pathol; 2014 Sep; 45(9):1928-35. PubMed ID: 25022570
[TBL] [Abstract][Full Text] [Related]
14. Surrogate markers and clinical indices, alone or combined, as indicators for endoscopic remission in anti-TNF-treated luminal Crohn's disease.
af Björkesten CG; Nieminen U; Turunen U; Arkkila P; Sipponen T; Färkkilä M
Scand J Gastroenterol; 2012 May; 47(5):528-37. PubMed ID: 22356594
[TBL] [Abstract][Full Text] [Related]
15. [Effectiveness of anti-TNF alpha antibodies in treatment of fistulizing Crohn's disease].
Rozpondek P; Zwolińska-Wcisło M; Przybylska M; Mach T
Przegl Lek; 2011; 68(9):602-5. PubMed ID: 22335009
[TBL] [Abstract][Full Text] [Related]
16. Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial.
Rutgeerts P; Van Assche G; Sandborn WJ; Wolf DC; Geboes K; Colombel JF; Reinisch W; ; Kumar A; Lazar A; Camez A; Lomax KG; Pollack PF; D'Haens G
Gastroenterology; 2012 May; 142(5):1102-1111.e2. PubMed ID: 22326435
[TBL] [Abstract][Full Text] [Related]
17. [Efficacy and safety of Adalimumab in Crohn's disease].
Serghini M; Haddad W; Jeddi H; Karoui S; Ben Mustapha N; Kallel L; Fekih M; Matri S; Boubaker J; Filali A
Tunis Med; 2012 Feb; 90(2):101-7. PubMed ID: 22407620
[TBL] [Abstract][Full Text] [Related]
18. Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn's disease: patient-reported outcomes of the CHARM trial.
Loftus EV; Feagan BG; Colombel JF; Rubin DT; Wu EQ; Yu AP; Pollack PF; Chao J; Mulani P
Am J Gastroenterol; 2008 Dec; 103(12):3132-41. PubMed ID: 18853973
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of infliximab and adalimumab in Crohn's disease: a single centre study.
Zorzi F; Zuzzi S; Onali S; Calabrese E; Condino G; Petruzziello C; Ascolani M; Pallone F; Biancone L
Aliment Pharmacol Ther; 2012 Jun; 35(12):1397-407. PubMed ID: 22519466
[TBL] [Abstract][Full Text] [Related]
20. Clinical experience with infliximab and adalimumab in a single-center cohort of patients with Crohn's disease.
Riis A; Martinsen TC; Waldum HL; Fossmark R
Scand J Gastroenterol; 2012 Jun; 47(6):649-57. PubMed ID: 22472026
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]